Research Projects & Grants

• An Open Label Safety Study of Intravenous Amiodarone HCL in Patients with Life-Threatening Ventricular Tachycardia/Fibrillation, Protocol No. 585-311-US, Role: Investigator, (12/1994 - 12/1995) Status: Completed
• CPI VENTAX PRx/ENDOTAK System Phase II, Role: Investigator, (11/1994 - 11/1995) Status: Completed
• Investigation of the Cadence Tiered Therapy Defibrillation System When Used with the CPI Endotak C Endocardial Defibrillation Lead System, Role: Investigator, (03/1994 - 03/1995) Status: Completed
• A Multicenter, Double-blind, Randomized Study to Compare the Safety and Efficacy of BG8967 with Heparin in Patients with Unstable Angina Undergoing Transluminal Angioplasty (PTCA), Role: PI, (02/1994 - 02/1995) Status: Completed

College/University

• A Randomized, Comparative Effectiveness Study of Complete Revascularization with Percutaneous Coronary Intervention to Treat Coronary Artery Disease vs Medical Management Alone in Patients with Symptomatic Aortic Valve Stenosis undergoing Elective Transfemoral Transcatheter Aortic Valve Replacement: The COMPLETE TAVR Study, Role: PI, University of British Columbia, (03/2025 - 03/2026) Status: Approved

For Profit Organization

• A Prospective, Multi-Center, Randomized, Controlled, Single Blind Clinical Trial Evaluating the Safety and Efficacy of the Cordella™ Pulmonary Artery Sensor System in New York Heart Association (NYHA) Class Ill Heart Failure Patients (PROACTIVE- HF Trial), Role: Investigator, Endotronix, Inc., (01/2025 - 01/2026) Status: Approved
• ARTEMIS D5130R00030: Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study, Role: Investigator, AstraZeneca (UK HQ), (07/2017 - 07/2018) Status: Completed
• AXERA Access safety and efficacy post endovascular intervention (ASPEN), Role: Investigator, Arstasis, Inc., (02/2015 - 02/2016) Status: Completed
• Humanitarian Use Device: Medtronic melody transcatheter pulmonary valve and Medtronic ensemble transcatheter valve delivery system, Role: Investigator, Medtronic, Inc., (09/2014 - 09/2015) Status: Completed
• The TRANSLATE-ACS study: Treatment with ADP receptor inhibitors: Longitudinal assessment of treatment patterns and events after acute coronary syndrome, Role: Investigator, Eli Lilly & Co., (05/2013 - 05/2014) Status: Completed
• A multicenter, randomized, double-blind, placebo-controlled study of the effects of KW-3902 injectable emulsion on heart failure signs and symptoms and renal function in subjects with acute heart failure syndrome and renal impairment who are hospitalized for volume overload and require intravenous diuretic therapy - Protocol Number: CKI-301, Role: Investigator, NovaCardia, (12/2008 - 12/2009) Status: Completed
• Follow-up serial infusions of Natrecor® (nesiritide) for the management of patients with heart failure - fusion II Protocol No. A034, Role: PI, Scios, Inc., (12/2006 - 12/2007) Status: Completed
• Multicenter, randomized, double-blind, placebo controlled study to evaluate the long term efficacy and safety of Oral Tolvaptan tablets in subjects hospitalized with worsening congestive heart failure (Protocol #156-03-236), Role: PI, Otsuka Pharmaceuticals, (10/2006 - 10/2007) Status: Completed
• Device evaluation of CONTAK RENEWAL(TM) 2 and EASYTRAK 2: Assessment of safety and effectiveness in heart failure, Role: PI, Guidant Corporation, (04/2006 - 04/2007) Status: Completed
• A pilot study to determine the effects of Carvedilol on left ventricular function in patients receiving Doxorubicin, Role: PI, GlaxoSmithKline, (12/2005 - 12/2006) Status: Completed
• Acute Decompensated Heart Failure National Registry (ADHERE®) Emergency Module (EM), Role: PI, Scios, Inc., (07/2005 - 07/2006) Status: Completed
• A multi-center, randomized, double-blind, parallel group, placebo-controlled study to assess the effects of Vasogen's Immune Modulation Therapy (IMT) on mortality and morbidity in patients with chronic heart failure - (ACCLAIM) Protocol 0202, Role: PI, Vasogen, Inc., (07/2005 - 07/2006) Status: Completed
• A double-blinded, randomized, placebo-controlled, multicenter study to evaluate the effects of treatment with 2 regimens of subcutaneous (SC) darbepoetin alfa (weight-based dosing and fixed dosing) on hemoglobin concentration response in subjects with symptomatic congestive heart failure (CHF) and anaemia - Protocol No. 20020171, Role: Investigator, Amgen, Inc., (04/2005 - 04/2006) Status: Completed
• A pilot study of the renal and systemic hemodynamic effects of nesiritide (human recombinant B-type natriuretic peptide) delivered via bilateral intra-renal infusion in patients with cardiac transplant, Role: PI, Flow Medica, Inc., (03/2005 - 03/2006) Status: Completed
• A double-blind, randomized, placebo-controlled, multicenter study to assess the impact of subcutaneous darbepoetin alfa treatment on exercise tolerance in subjects with symptomatic congestive heart failure and anemia. Protocol No. 20010170 STAMINA-HeFT (Study of Anemia in Heart Failure - Heart Failure Trial), Role: Investigator, Amgen, Inc., (12/2004 - 12/2005) Status: Completed
• Multi-center, randomized, double-blind, placebo-controlled study to evaluate the effect of single oral Tolvaptan tablets on hemodynamic parameters in subjects with heart failure, protocol no. 156-04-247, Role: Investigator, Otsuka Maryland Research Institute, (11/2004 - 11/2005) Status: Completed
• An open, nonrandomized comparison of pharmacokinetic profiles of carvedilol (SK&F 105517) MR and IR on repeat dosing in chronic CHF patients and survivors of an acute MI with LVD - Protocol No.105517, Role: PI, GlaxoSmithKline, (10/2004 - 10/2005) Status: Completed
• "The Studies of Oral Enoximone Therapy in Advanced Heart Failure" (ESSENTIAL) - A Phase III, Randomized, Double-blind, Multicenter, Parallel Group, Placebo-Controlled Study of Oral Enoximone vs. Placebo in Advanced Chronic Heart Failure Subjects (Protocol No. My-021), Role: PI, Myogen, Inc., (09/2004 - 09/2005) Status: Completed
• Prevention of restenosis by tranilast and its outcomes (PRESTO), Role: Investigator, Smithkline Beecham, (04/2000 - 04/2001) Status: Completed
• Evaluation of acute and chronic lead measurements using the Guidant/CPI Selute Picotip models 4033/4034/4035 (Protocol version dated 08/06/1998)., Role: PI, Guidant Corporation, (02/1999 - 02/2000) Status: Completed
• DDD Versus DDDR Pacing: A Quality of Life Study, Role: Investigator, Pacesetter Systems, Inc., (08/1998 - 08/1999) Status: Completed
• Microny SR+ (model 2425T) and the Regency SR+ (2400L) single-chamber rate-adaptive pulse generators with autocapture, Role: Investigator, Pacesetter Systems, Inc., (05/1998 - 05/1999) Status: Completed
• Comparison of the one-button follow-up versus standard follow-up for the guidant/CPI Vigor DR models 1230/1232/1235 and Vigor DDD models 950/955 pacemakers, Role: Investigator, Guidant Corporation, (10/1997) Status: Completed
• Paragon A: A Randomized, Double-Blind, Placebo Controlled Study with Two Doses of Lamifiban (RO 44-9883), with or without Heparin, in Patients with Acute Coronary Syndrome without ST-Segment Elevation (Unstable Angina, Non-Q Wave Myocardial Infarction), Role: Investigator, Hoffmann-La Roche Inc., (11/1996 - 11/1997) Status: Completed
• Trilogy DR+ models 2360L and 2364L dual chamber pulse generators, Role: Investigator, Pacesetter Systems, Inc., (10/1996 - 10/1997) Status: Completed
• Multicenter, Double-Blind Randomized, Dose-Ranging Trial of BMS 200,980 in Subjects with Acute Myocardial Infarction, Role: Investigator, Pharmaceutical Research & Manufacturers of America (PhRMA) Foundation, (01/1996 - 01/1997) Status: Completed
• Comparison of Programming Features and Modes for Cardiac Pacemakers Study Protocol, Role: Investigator, Pacesetter Systems, Inc., (12/1995 - 12/1996) Status: Completed
• A randomized double-blind, placebo-controlled study of two intravenous dosing regimens of h5G1.1-scFc in patients with acute myocardial infarction undergoing percutaneous transluminal coronary angioplasty reperfusion therapy, Role: PI, Procter & Gamble Company, Status: Completed
• A randomized, double-blind, placebo-controlled study of two intravenous dosing regimens of h5G1.1scFv in patients with acute myocardial infarction undergoing thrombolytic reperfusion therapy, Role: PI, Procter & Gamble Company, Status: Completed

Internal

• HUD: PK Papyrus Covered Coronary Stent System, Role: Investigator, LLU Dept. of Medicine, (04/2025 - 04/2026) Status: Approved
• Database for patients enrolled in the cardiomyopathy clinic, Role: Investigator, LLU Dept. of Medicine, (08/2022 - 08/2023) Status: Completed
• National cardiogenic shock initiative, Role: Investigator, LLU Dept. of Cardiology, (07/2020 - 07/2021) Status: Completed
• Living with advanced heart failure: the patient experience, Role: PI, LLU Dept. of Cardiology, (10/2007 - 10/2008) Status: Completed
• Predictability of coronary heart disease event rates by common carotid artery intima-media thickness alone compared to combined three-site sampling in the atherosclerosis risk in communities (ARIC) study, Role: Investigator, LLU Center for Health Research, (06/2006) Status: Completed
• B-type natriuretic peptide and prognosis in congestive heart failure, Role: Investigator, LLU School of Medicine, (02/2005 - 02/2006) Status: Completed
• Insulin-like growth factors and the binding proteins response to myocardial ischemia and coronary plaque rupture, Role: Investigator, LLU Dept. of Cardiopulmonary Sciences, (06/1999 - 06/2000) Status: Completed
• Differences in Coronary Plaque Morphology Characteristics and Total Plaque Burden Between Diabetic and Non-Diabetic Patients, Role: Investigator, LLU Dept. of Medicine, (11/1997 - 11/1998) Status: Completed
• Multicenter-Pacing Therapy for Hypertrophic Cardiomyopathy (M-PATHY), Role: Investigator, LLU Dept. of Medicine, (03/1996 - 03/1997) Status: Completed
• Compassionate/Emergency Use of the Edwards 29 mm SAPIEN XT™ THV model 9300TFX and delivery system for transcatheter aortic valve replacement (TAVR), Role: PI, LLU Dept. of Medicine, Status: Completed
• Compassionate/emergent use of the 29mm SAPIEN XT THV Model 9300TFX and Delivery System, Role: PI, LLU Dept. of Medicine, Status: Completed

Non-Profit Organization

• Cardiovascular inflammation reduction trial (CIRT): a randomized, double-blind, placebo-controlled, event-driven trial of weekly low-dose Methotrexate(LDM) in the prevention of cardiovascular events among stable coronary artery disease patients with type 2 diabetes or metabolic syndrome, Role: PI, Brigham & Women's Hospital, (08/2017 - 08/2018) Status: Completed
• Cardiovascular Inflammation Reduction Trial (CIRT), Role: Principal Investigator, Brigham & Women's Hospital, (05/2014 - 04/2018) Status: Closed
• Pain assessment, incidence and nature in heart failure (PAIN-HF), Role: Investigator, Mayday Fund, (05/2007 - 05/2008) Status: Completed
• COMPASS-HF (Chronicle® Offers Management to Patients with Advanced Signs & Symptoms of Heart Failure), Role: PI, Medtronic Foundation, (06/2005 - 06/2006) Status: Completed
• Clinical investigation of Model 5044 transvenous tined steroid pacing lead, Role: Investigator, Medtronic Foundation, (04/1999 - 04/2000) Status: Completed
• Double-blind, randomized, multicenter trial of single-bolus lanoteplase versus accelerated alterplase for the treatment of subjects with acute myocardial infarction (inTIME-II). Protocol No. 981-117/258-102, version 02/25/98, Role: Investigator, Bristol-Myers Squibb Foundation, Inc., (07/1998 - 06/1999) Status: Completed
• Clinical study of the Medtronic (KAPPA) KDR 700/KVDD 700 pulse generator, Role: Investigator, Medtronic Foundation, (06/1998 - 06/1999) Status: Completed
• Clinical investigation of Model 5054/5554 transvenous tined steroid eluting pacing lead, Role: Investigator, Medtronic Foundation, (05/1998 - 05/1999) Status: Completed
• Cholesterol and recurrent events (CARE): an inter-continental secondary prevention trial of lowering blood cholesterol after myocardial infarction, Role: Investigator, Bristol-Myers Squibb Foundation, Inc., (05/1997 - 05/1998) Status: Completed